Kathleen Francissen

Dr. Francissen has been dedicated to the development of advanced therapy medicinal products (ATMP) for the past several years, thus leveraging >25 years of experience in biopharmaceutical development. She serves as the Rapporteur of the ICH CGT DG, representing the Biotechnology Innovation Organization (BIO), and is responsible for leading the technical discussions.

Appearances